Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–42 of 42 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Infectious Colitis Clear all

Conditions: Clostridium Difficile Colitis
Interventions: FMT, placebo; Biological
Lead sponsor: MemorialCare Health System; Other
Eligibility: 1 Year to 21 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn Disease, Ulcerative Colitis, Plaque Psoriasis, Pediatric Plaque Psoriasis, Pediatric Crohns Disease, Hidradenitis Suppurativa, Non-infectious Uveitis
Interventions: 40 mg MSB11022; Drug
Lead sponsor: Fresenius Kabi SwissBioSim GmbH; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 216 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Lenexa, Kansas • Salt Lake City, Utah

Conditions: Colitis, HIV Infections
Interventions: Glutamic acid hydrochloride, Ganciclovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 5
States / cities: Birmingham, Alabama • San Francisco, California • St Louis, Missouri + 2 more

Conditions: Clostridium Difficile Infection
Interventions: Bismuth Subsalicylate, standard antibiotic therapy; Drug
Lead sponsor: Bassett Healthcare; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Cooperstown, New York

Conditions: Clostridium Difficile Infection, Infection, Communicable Diseases
Interventions: RBX2660; Drug
Lead sponsor: Rebiotix Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 793 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 46
States / cities: Phoenix, Arizona • North Little Rock, Arkansas • Oxnard, California + 43 more

Conditions: Moderate Clostridium Difficile Infection
Interventions: LFF571, Vancomycin (POC); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 14
States / cities: Palm Desert, California • Bristol, Connecticut • Clearwater, Florida + 11 more

Conditions: Clostridium Difficile Infection (CDI)
Interventions: RBX2660, Placebo, Open label RBX2660 (only for confirmed CDI recurrence); Drug
Lead sponsor: Rebiotix Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 60
States / cities: Athens, Alabama • Dothan, Alabama • Phoenix, Arizona + 54 more

Conditions: Dysbiosis, Clostridium Difficile, Pet-Human Bonding, Antibiotic-Associated Colitis
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Infectious, Colitis, Gastroenteritis
Interventions: Not listed
Lead sponsor: Luminex Molecular Diagnostics; Industry
Eligibility: Not listed
Enrollment: 1,534 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 4
States / cities: Tucson, Arizona • St Louis, Missouri • Nashville, Tennessee + 1 more

Conditions: Gastroenteritis, Infectious Colitis
Interventions: Not listed
Lead sponsor: Luminex Corporation; Industry
Eligibility: Not listed
Enrollment: 1,021 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 4
States / cities: Tampa, Florida • Indianapolis, Indiana • Albuquerque, New Mexico + 1 more

Conditions: Inflammatory Bowel Diseases, Clostridium Difficile Infection
Interventions: Bezlotoxumab, Placebo, Fecal Microbiota Transplantation; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Inflammatory Bowel Disease (IBD), Clostridioides Difficile Infection
Interventions: Vancomycin (POC), Fidaxomicin; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Clostridium Difficile Infection, Diarrhea
Interventions: Clostridium difficile toxoids A and B (Low-dose with adjuvant), Clostridium difficile toxoids A and B (Low-dose without adjuvant), Clostridium difficile toxoids A and B (high-dose with adjuvant), Clostridium difficile toxoids A and B (high-dose without adjuvant), Placebo: 0.9% normal saline; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 650 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 30
States / cities: Redding, California • Bristol, Connecticut • Stamford, Connecticut + 25 more

Conditions: Clostridium Enterocolitis, Pseudomembranous Colitis, Antibiotic-Associated Colitis
Interventions: Metronidazole; Drug
Lead sponsor: Michael E. DeBakey VA Medical Center; Federal
Eligibility: 18 Years to 64 Years
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), Crohn's Disease (CD), Anal Human Papillomavirus
Interventions: Venous blood samples, anal swab samples, vaginal swab samples, high resolution anoscopy (HRA), anal biopsy samples; Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 65 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease, C. Diff. Infections
Interventions: Bezlotoxumab; Biological
Lead sponsor: David Binion, MD; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Clostridium Difficile Infection
Interventions: Not listed
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Herpes Zoster, Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Interventions: Not listed
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 35 Years to 49 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Madison, Wisconsin

Search by objective public record fields.

Stool Transplant in Pediatric Patients With Recurring C. Difficile Infection

Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS

A Randomized Comparative Pharmacokinetic Study of Oral Ganciclovir After Treatment With Intravenous Ganciclovir for Cytomegalovirus Gastrointestinal Disease in AIDS Patients

Use of Bismuth Subsalicylate in Clostridium Difficile Colitis

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS)

Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3)

REMBRANDT: REcovery of the MicroBiome fRom Antibiotics for Dental implanTs

A Two-Arm, Multi-Centre Clinical Evaluation of the xTAG Gastrointestinal Pathogen Panel

A Multi-Site Clinical Evaluation of the ARIES Clostridium Difficile Assay in Symptomatic Patients

ICON-2: FMT and Bezlotoxumab Compared to FMT and Placebo for Patients With IBD and CDI

Use of Fidaxomicin Compared to Vancomycin for Decolonization of C. Difficile in Patients With Inflammatory Bowel Disease

Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults

Response of Clostridium Difficile Infection to Metronidazole Therapy

Anal Human Papillomavirus in Inflammatory Bowel Disease Study

Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).

Pathogenic Mechanisms in C Diff Infection and Colitis

Identifying Young Inflammatory Bowel Disease Patients at Risk for Herpes Zoster